Collaboration to leverage world class capabilities of Molecular Partners DARPin platform with Novartis’ in radioligand therapy to explore the potential for novel targeted therapies for cancer Novartis will pay $20 million upfront, commercial royalties up to low double-digits, and milestone

Laboratory studies using full Omicron pseudovirus confirm ensovibep maintains ability to neutralize the variant with very high potency, relative to substantial reductions in neutralizing potency across numerous anti-SARS-CoV-2 antibody drugs Ensovibep continues to retain potent neutralization

Program overview and study design for MP0317 to be presented at ESMO Immuno-Oncology Preclinical data supporting novel mechanism of AML candidate MP0533 to be presented at ASH Oncology R&D Day to review cancer therapeutic portfolio and strategy on December 15, 2021 ZURICH-SCHLIEREN, Switzerland and

First presentation of data from patients treated with ensovibep demonstrate the candidate to be safe and well-tolerated All patients exhibited reductions in viral load and complete COVID-19 clinical symptom recovery Additional data presented includes review of the supportive Phase 1 study of

Research collaboration with leading acute myeloid leukemia (AML) experts, Professor Ochsenbein and Professor Riether from the Department of Medical Oncology, Inselspital, Bern University Hospital, Switzerland, to support advancement of drug development process MP0533 is designed to target three

Ensovibep retains activity with regard to all relevant individual positions mutated in Omicron, the newly discovered viral variant of concern Testing on the full Omicron variant has initiated, with results expected in the coming weeks Global Phase 2-3 EMPATHY clinical study ongoing with topline

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer,

Following the futility analysis, the independent Data and Safety Monitoring Board (DSMB) recommends that the recruitment of patients in the ensovibep arm of ACTIV-3 not continue in hospitalized patients The global phase 2-3 EMPATHY study in non-hospitalized patients is still ongoing with topline

Second immuno-oncology DARPin candidate to enter the clinic; combines immune stimulation with validated tumor-localizing technology Preclinical data support potential to deliver tumor-localized immune activation while avoiding systemic toxicity seen with other CD40-targeting agents ZURICH

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR:   Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics,